MedTrace Logo

Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain

NCT05615441 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2022-11-14

No results posted yet for this study

Summary

This study aims to investigate whether the use of nociception monitoring during general anesthesia with remimazolam-based total intravenous anesthesia has an effect on intraoperative opioid requirements and postoperative pain. This study is a randomized trial with a 50% probability of being assigned to either group. Randomization will be done by an anesthesiologist not involved in anesthesia or postoperative outcome assessment. Patients and the investigator in charge of postoperative outcomes assessment will be blinded to group allocation.

Conditions

  • Adult Patients Aged 19-64, Scheduled for Elective Arthroscopic Knee Surgery

Interventions

DEVICE

Analgesia Nociception Index monitor

Patients will receive remimazolam-based total intravenous general anesthesia with nociception monitoring with the ANI monitor

DEVICE

Standard monitoring

Patients will receive remimazolam-based total intravenous general anesthesia based on hemodynamic monitoring and without nociception monitoring

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Seokyung Shin · Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-02
Primary Completion
2024-11-01
Completion
2024-11-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05615441 on ClinicalTrials.gov